The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients

Anesthesia and Analgesia

Volumn 99, Issue 4, 2004, Pages 1086-1089

  Leykin, Yigal ^a   Pellis, Tommaso ^b   Lucca, Mariella ^a   Lomangino, Giacomina ^b   Marzano, Bernardo ^a   Gullo, Antonino ^b  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROPOFOL; REMIFENTANIL; ROCURONIUM;

ACCELEROMETER; ADULT; ANESTHESIA INDUCTION; ANESTHETIC RECOVERY; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MORBIDITY; MUSCLE TWITCH; MYOGRAPHY; NEUROMUSCULAR TRANSMISSION; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; AGING; ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; BODY MASS INDEX; BODY WEIGHT; CALIBRATION; FEMALE; GASTRIC BYPASS; HUMANS; LAPAROSCOPY; MIDDLE AGED; NEUROMUSCULAR NONDEPOLARIZING AGENTS; OBESITY, MORBID; SEX CHARACTERISTICS; STOMACH;

EID: 4644297613     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000120081.99080.C2     Document Type: Article

References (15)

1. World Health Organization. Report of a WHO consultation on obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 1997.
2. National Institutes of Health consensus development conference statement: gastrointestinal surgery for severe obesity. Obes Surg 1991;1:243-56.
3. Kral JG. Morbid obesity and related health risks. Ann Intern Med 1985;103:1043-7.
4. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997;327:396-407.
5. Balsiger BM, Murr MM, Poggio JL, Sarr MG. Bariatric surgery: surgery for weight control in patients with morbid obesity. Med Clin North Am 2000;84:477-89.
6. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 2000;39:215-31.
7. Abernathy DR, Greenblatt DJ, Divoll M, et al. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 1981;217:681-5.
8. Puhringer FK, Keller C, Kleinsasser A, et al. Pharmacokinetics of rocuronium bromide in obese patients. Eur J Anaesthesiol 1999; 16:507-10.
9. Wierda JMKH, Kleef UW, Lambalk LM, et al. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991;38:430-5.
10. Puhringer FK, Khuenl-Brady KS, Mitterschiffthaler G. Rocuronium bromide: time-course of action in underweight, normal weight, overweight and obese patients. Eur J Anaesthesiol 1995; 12:107-10.
11. Pino RM, Ali HA, Denman WT, et al. A comparison of the intubation conditions between mivacurium and rocuronium during balanced anesthesia. Anesthesiology 1988;88:673-8.
12. Weinstein JA, Matteo RS, Ornstein E, et al. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. Anesth Analg 1988;67:1149-53.
13. Statistics Bulletin of Metropolitan Life Insurance Co., December 1959.
14. Savarese JJ, Caldwell JE, Lien CA, et al. Pharmacology of muscle relaxants and their antagonists. In: Miller RD, ed. Anesthesia. Philadelphia: Churchill Livingstone, 2000:412-90.
15. Fisher DM, Rosen JI. A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. Anesthesiology 1987;65:286-91. .0